Elekta

Corporate brand

Swedish medical technology company developing radiation therapy, radiosurgery, brachytherapy and oncology information systems.

Last updated August 31, 2026

AI crawler reads

No AI crawler has read this profile yet.

Overview

Elekta is a Swedish medical technology company focused on equipment, software and clinical-management solutions for radiation therapy, radiosurgery and the treatment of cancer and neurological disorders. Headquartered in Stockholm and listed on Nasdaq Stockholm, the company serves hospitals, cancer centers and specialist healthcare providers across international markets. Its installed base includes approximately 7,500 devices and software solutions, and Elekta states that its technologies support treatment for more than two million patients annually in roughly 130 countries. The company has more than 4,000 employees and offices in more than 40 countries. The business originated in the work of Swedish neurosurgeon Lars Leksell, whose research into stereotactic neurosurgery and focused radiation led to the development of the Leksell Stereotactic System and Gamma Knife. Lars Leksell and his son Laurent Leksell established Elekta in 1972 to commercialize these technologies. The company initially built its identity around non-invasive and minimally invasive treatment of brain disorders, including tumors, arteriovenous malformations and certain functional neurological conditions. Gamma Knife became the best-known expression of this heritage: it delivers precisely focused gamma radiation to a defined intracranial target while seeking to limit exposure to surrounding tissue. Over time, Elekta expanded from radiosurgery into a broader oncology technology platform. Its portfolio now includes linear accelerators for external-beam radiotherapy, magnetic-resonance-guided radiation therapy, brachytherapy systems, treatment-planning applications, oncology information systems and related imaging and workflow tools. Products such as Versa HD, Elekta Unity, Harmony and Evo address different external-beam treatment requirements, while Flexitron, specialized applicators and Oncentra Brachy support high-dose-rate brachytherapy. The MOSAIQ oncology information system and Monaco treatment-planning system extend the business into clinical workflow, data and treatment design. Acquisitions have been an important part of the company’s development. Elekta acquired Nucletron in 2011, strengthening its position in brachytherapy, and has also acquired or integrated businesses and technologies associated with oncology information management, treatment planning, distribution and service. The company has cited acquisitions including IMPAC Medical Systems, CMS, ProKnow Systems, 3D Line Medical Systems, the Beijing Medical Equipment Institute and the radiotherapy division of Philips Medical Systems among its expansion activities. Elekta positions itself as a specialist provider of precision oncology and neurotechnology rather than as a general medical-equipment conglomerate. Its strategy combines capital equipment, software, treatment know-how, service and partnerships with hospitals and academic institutions. A notable example is Elekta Unity, a high-field MR-linac developed with UMC Utrecht and Philips that combines magnetic resonance imaging with a linear accelerator, enabling clinicians to visualize anatomy during radiation treatment. The company also emphasizes access to cancer care, sustainability and social impact. Its sustainability-linked financing included a social performance objective connected with expanding cancer-care access in underserved markets, while the Elekta Foundation supports projects with governments, nongovernmental organizations and healthcare providers in low- and middle-income countries. Elekta remains an active international medical-technology brand whose principal business is the delivery of precision radiation and oncology solutions.

History

Elekta was established in 1972 by Swedish neurosurgeon Lars Leksell and his son Laurent Leksell. The company was created to commercialize technologies developed from Leksell’s research into stereotactic neurosurgery, particularly the Leksell Stereotactic System and Gamma Knife. These technologies sought to treat precisely localized brain conditions without conventional open surgery. The founding concept gave Elekta an enduring focus on precision, non-invasive treatment and specialist neuro-oncology. Gamma Knife’s technical lineage reaches back to work conducted at the Karolinska Institute in Stockholm during the mid-twentieth century. Lars Leksell collaborated with neurosurgeon Ladislau Steiner and radiobiologist Börje Larsson on focused radiation technology. The first Gamma Knife system was developed in Sweden in the 1960s, and the technology later reached the United States through an arrangement involving American neurosurgeon Robert Wheeler Rand and Leksell. A system was installed at the University of California, Los Angeles, in 1979, helping establish the technology internationally. During Laurent Leksell’s period as chief executive, which lasted until 2005, Elekta developed from a specialist radiosurgery enterprise into a publicly traded medical-technology group with an expanding international workforce. The company was listed on the Nordic exchange in 1994 and subsequently became a constituent of the modern Nasdaq Stockholm market. Its business broadened beyond cranial radiosurgery into external-beam radiotherapy, treatment planning, oncology information management, brachytherapy and clinical services. Elekta’s expansion has included acquisitions of technology companies, distributors and service organizations. The 2011 acquisition of Nucletron was particularly significant because it made Elekta a major global provider of brachytherapy systems. Other businesses and technologies associated with Elekta’s expansion include IMPAC Medical Systems, CMS, ProKnow Systems, 3D Line Medical Systems, the Beijing Medical Equipment Institute and the radiotherapy division of Philips Medical Systems. These transactions supported the development of a broader product and software ecosystem around cancer treatment. The company’s product history includes the Versa HD linear accelerator, launched in 2013, and Elekta Unity, introduced in 2018 after development work with UMC Utrecht and Philips. Unity combined high-field magnetic-resonance imaging with a linear accelerator, allowing treatment teams to observe anatomy during radiotherapy. Elekta later introduced Harmony in 2020 and Evo CT-Linac in 2024, continuing its development of image-guided and external-beam treatment platforms. Its portfolio also includes the Flexitron afterloader, brachytherapy applicators, Oncentra Brachy, MOSAIQ and Monaco. Elekta has also made social access to cancer care part of its corporate agenda. The company has described a global environmental policy covering product and service life cycles and established the Elekta Foundation after shareholder approval in 2021. The foundation works with public authorities, nongovernmental organizations and healthcare providers on initiatives intended to improve cancer treatment access in lower-income markets. Elekta remains headquartered in Stockholm, operates through offices in more than 40 countries and supplies equipment and software used by healthcare providers around the world.

2024
Evo CT-Linac launches
[1]Elektaen.wikipedia.org
Elekta launches Evo, a CT-linac platform for image-guided radiation therapy.
2021
Elekta Foundation is approved
[1]Elektaen.wikipedia.org
Shareholders approve a foundation intended to support improved cancer-care access in low- and middle-income countries.
2020
Harmony launches
[1]Elektaen.wikipedia.org
Elekta adds Harmony to its linear-accelerator portfolio.
2018
Elekta Unity launches
[1]Elektaen.wikipedia.org
Elekta introduces its high-field MR-linac, combining magnetic-resonance imaging and radiation treatment.
2013
Versa HD launches
[1]Elektaen.wikipedia.org
Elekta introduces the Versa HD linear accelerator for external-beam radiotherapy.
2011
Nucletron acquisition
[1]Elektaen.wikipedia.org
Elekta acquires Nucletron and substantially strengthens its brachytherapy business.
1994
Elekta lists on the Nordic exchange
[1]Elektaen.wikipedia.org
The company becomes publicly traded on the Nordic exchange, now Nasdaq Stockholm.
1979
Gamma Knife reaches the United States
[1]Elektaen.wikipedia.org
A Gamma Knife system is brought to UCLA, helping extend the Swedish radiosurgery technology into the U.S. healthcare market.
1972
Elekta is founded
[1]Elektaen.wikipedia.org
Lars Leksell and Laurent Leksell establish Elekta to commercialize stereotactic neurosurgery and Gamma Knife technologies.

Products and positioning

A specialist, high-precision medical-technology provider for radiation oncology, radiosurgery, brachytherapy and oncology workflow management.

Stereotactic radiosurgery
Leksell Gamma Knife
A radiosurgery platform that delivers many focused gamma-ray beams to a precisely defined intracranial target. It is used for selected brain tumors, arteriovenous malformations and certain functional neurological disorders, providing a non-invasive alternative to some forms of open neurosurgery.
Neurosurgical positioning system
Leksell Stereotactic System
An arc-based stereotactic frame and positioning system used to establish precise three-dimensional coordinates during minimally invasive neurosurgical and radiosurgical procedures.
Linear accelerator · 2013
Versa HD
A linear-accelerator platform for external-beam radiotherapy, including highly conformal and stereotactic treatment techniques. It is designed to support a broad range of oncology workflows and treatment protocols.
MR-guided linear accelerator · 2018
Elekta Unity
A high-field MR-linac that combines 1.5-tesla magnetic-resonance imaging with a linear accelerator. The system enables clinicians to visualize anatomy during treatment and adapt radiation delivery to changing patient or tumor conditions.
Linear accelerator · 2020
Elekta Harmony
A linear-accelerator platform introduced for external-beam radiotherapy. Harmony is intended to support efficient clinical workflows and a range of conventional, conformal and image-guided treatment approaches.
CT-guided linear accelerator · 2024
Evo CT-Linac
A CT-linac platform launched for image-guided radiation therapy. It extends Elekta’s external-beam portfolio with integrated computed-tomography imaging intended to support treatment positioning and verification.
Brachytherapy afterloader
Flexitron
A remote afterloading system used to deliver a planned radiation dose through applicators positioned in or near the treatment area. It forms part of Elekta’s brachytherapy portfolio following the Nucletron acquisition.
Brachytherapy planning software
Oncentra Brachy
Treatment-planning software for brachytherapy procedures, supporting the preparation and management of radiation-dose delivery plans.
Oncology information system
MOSAIQ
An oncology information system used to manage clinical workflows, patient information and treatment-related processes across radiation oncology services.
Treatment-planning software
Monaco
A radiation-treatment planning system used to design and optimize dose delivery for external-beam radiotherapy and related oncology procedures.

Controversies

2021
PTAB rules Elekta patent claims invalid
The Patent Trial and Appeal Board ruled in ZAP Surgical's favor on March 30, 2021, finding Elekta's patent claims invalid in a dispute involving ZAP Surgical's ZAP-X platform.
Source

2021Elekta Foundation access-to-care initiative
Low- and middle-income countries
Elekta established a foundation intended to work with governments, nongovernmental organizations and healthcare providers on programs that expand access to cancer care.
Outcome. The foundation became part of Elekta’s social and sustainability agenda.
Source

Brand decisions

2024
Launch Evo CT-LinacProduct launch
Background
Image guidance and treatment verification are central requirements in modern external-beam radiotherapy.
Action taken
Elekta introduced Evo, a CT-linac platform for image-guided radiation therapy.
Aftermath
Evo expanded the company’s linear-accelerator and imaging portfolio.
Source
2021
Establish the Elekta FoundationStrategy
Background
Elekta identified unequal access to cancer treatment as a social and healthcare challenge.
Action taken
Shareholders approved the Board’s proposal to establish the Elekta Foundation.
Aftermath
The foundation was designated to support cancer-care access projects in partnership with public, nonprofit and healthcare organizations.
Source
2021
Issue social sustainability-linked bondsStrategy
Background
Elekta linked part of its financing strategy to environmental, social and governance objectives.
Action taken
The company issued sustainability-linked bonds with a social performance indicator connected to expanding global access to cancer care.
Aftermath
The financing was presented as supporting access to care in underserved markets.
Bond principal. SEK 1.5 billion (2021)
Source
2018
Introduce Elekta Unity MR-linacProduct launch
Background
Radiation oncology was increasingly incorporating real-time or near-real-time imaging to improve treatment targeting.
Action taken
Elekta launched Unity, a high-field MR-linac developed with UMC Utrecht and Philips.
Aftermath
The product extended Elekta into integrated magnetic-resonance-guided radiation therapy.
Source
2011
Acquire NucletronM&A
Background
Elekta sought to broaden its oncology portfolio and strengthen its position in brachytherapy.
Action taken
The company acquired Nucletron, integrating brachytherapy systems, software and related expertise into its business.
Aftermath
The transaction made Elekta a global market leader in brachytherapy devices, according to the reference material.
Source

Recent events

2021.09.02
Reported2021.09.02
Elekta acquires Turkish distributor Özyürek A.Ş.[4]Elekta 收购土耳其经销商 Özyürek A.Ş.prnewswire.com
Elekta announced that it had acquired its long-time partner and Turkish distributor of neurosurgery solutions, Özyürek Mümessillik ve Dış Ticaret A.Ş. Elekta said the acquisition would improve its regional market access and strengthen customer relationships.
2021.03.30
Reported2021.04.06
PTAB rules Elekta patent claims invalid[3]PTAB rules Elekta patent claims invalidprweb.com
The Patent Trial and Appeal Board ruled in ZAP Surgical's favor on March 30, 2021, finding Elekta's patent claims invalid in a dispute involving ZAP Surgical's ZAP-X platform.
2021.02.25
Reported2021.02.25
Elekta appoints Johan Adebäck as permanent CFO[5]Elekta任命Johan Adebäck为正式首席财务官prnewswire.com
Elekta announced that Johan Adebäck was appointed permanent Chief Financial Officer with immediate effect, after serving as Acting CFO since June 2, 2020.
2019.12.23
Reported2019.12.25
Qixi Group and Elekta form strategic partnership[6]七喜集团与医科达达成战略合作finance.sina.com.cn
Qixi Group and Elekta (China) Investment Co., Ltd. signed a strategic partnership to promote the application of radiotherapy technology in China. The agreement includes Qixi Group purchasing 10 linear accelerators from Elekta (China) and cooperation in talent development and research.
2019.12.16
Reported2019.12.16
FDA clears diffusion-weighted imaging for Elekta Unity[7]FDA批准Elekta Unity使用弥散加权成像prnewswire.com
Elekta announced that it received FDA 510(k) premarket notification for interpreting diffusion-weighted MR images obtained with Elekta Unity, expanding the system's clinical use to include assessment of tumor response during therapy.
2019.12.13
Reported2019.12.13
Elekta and ViewRay announced MR-guided radiation therapy collaboration[8]Elekta与ViewRay宣布开展磁共振引导放射治疗合作itnonline.com
Elekta announced that it had signed a non-binding memorandum of understanding with ViewRay to advance knowledge and application of MR-guided radiation therapy. The companies said the collaboration was subject to definitive documentation.
2019.12.02
Reported2019.12.02
ViewRay and Elekta announced a collaboration memorandum[9]ViewRay 与 Elekta 宣布签署合作谅解备忘录prnewswire.com
ViewRay announced that it signed a non-binding memorandum of understanding with Elekta for collaboration to advance knowledge and use of MR-guided radiation therapy. The collaboration is subject to execution of definitive documentation.
2019.12
Reported2020.01.15
Elekta signs agreement with HEDY Group for cancer-treatment systems[10]Elekta与HEDY Group签署癌症治疗系统协议prnewswire.com
Elekta and HEDY Group signed an agreement for 10 linear accelerators, treatment-planning systems, oncology information systems, and service for each linac. The source says the investment agreement was signed in December 2019.
2019.10.23
Reported2019.10.23
Elekta wins TSIA STAR award[11]Elekta获TSIA STAR奖prnewswire.com
The Technology Services Industry Association presented Elekta with its STAR award, recognizing the company in Field Service.
2019.10.17
Reported2019.10.17
Elekta Unity receives IOP Business Innovation Award[12]Elekta Unity 获得物理研究所商业创新奖prnewswire.com
Elekta announced that its Elekta Unity magnetic resonance radiation therapy system received the Institute of Physics Business Innovation Award 2019.

Sources12 sources

Cite this profile: Cite the canonical profile. /brand-wiki/elekta · Editorial policy · How profiles are compiled